972 related articles for article (PubMed ID: 17036267)
1. [Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil].
Sixdorf U; Bauer H; Märker-Hermann E
Dtsch Med Wochenschr; 2006 Oct; 131(41):2266-9. PubMed ID: 17036267
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
3. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Dittrich K; Ross S; Benz K; Amann K; Dötsch J
Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
Dall'Era M
Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
7. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
Ginzler EM; Wofsy D; Isenberg D; Gordon C; Lisk L; Dooley MA;
Arthritis Rheum; 2010 Jan; 62(1):211-21. PubMed ID: 20039429
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
9. Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis.
Tse KC; Tang CS; Lio WI; Lam MF; Chan TM
Lupus; 2006; 15(6):371-9. PubMed ID: 16830884
[TBL] [Abstract][Full Text] [Related]
10. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
11. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
[TBL] [Abstract][Full Text] [Related]
12. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis.
Gadakchi L; Hajialilo M; Nakhjavani MR; Abedi Azar S; Kolahi S; Gojazadeh M; Ebrahimi AA; Malek Mahdavi A; Noshad H; Khabbazi A
Iran J Kidney Dis; 2018 Oct; 12(5):288-292. PubMed ID: 30367020
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological therapy of lupus nephritis.
Fine DM
JAMA; 2005 Jun; 293(24):3053-60. PubMed ID: 15972568
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.
Lau KK; Ault BH; Jones DP; Butani L
J Pediatr Health Care; 2008; 22(5):282-8. PubMed ID: 18761229
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Buratti S; Szer IS; Spencer CH; Bartosh S; Reiff A
J Rheumatol; 2001 Sep; 28(9):2103-8. PubMed ID: 11550982
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
Mendonca S; Gupta D; Ali S; Gupta P
Saudi J Kidney Dis Transpl; 2017; 28(5):1069-1077. PubMed ID: 28937065
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for lupus nephritis: an update.
Mok CC
Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748
[TBL] [Abstract][Full Text] [Related]
20. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
